
Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimates

I'm PortAI, I can summarize articles.
Recursion reports second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million. Recursion reports a second-quarter loss of 41 cents per share, missing estimates for a loss of 34 cents per share. The market's back, and these 3 income stocks are thriving. See them here→
